Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Drug |
Pharmacologic Class |
Indication |
More Information |
| Dermatological Disorders | |||
| Opzelura (ruxolitinib cream) | Janus kinase inhibitor | Treatment of nonsegmental vitiligo in patients 12 years of age and older. | Opzelura Drug Monograph |
| Zoryve (roflumilast cream) | Phosphodiesterase-4 inhibitor | Treatment of plaque psoriasis in patients 12 years of age and older. | Zoryve Cream Approved for Plaque Psoriasis |
| Neurologic Disorders | |||
| Zonisade (zonisamide oral suspension) | Carbonic anhydrase inhibitor | Adjunctive therapy for the treatment of partial-onset seizures in patients 16 years of age and older. | Oral Suspension Formulation of Zonisamide Gets FDA Approval |
| Oncology | |||
| Xalkori (crizotinib capsules) | Tyrosine kinase inhibitor | Treatment of patients 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase-positive myofibroblastic tumor. | Xalkori Drug Monograph |
| Diagnostic Agents | |||
| Bludigo (indigotindisulfonate sodium injection) | Diagnostic dye | For use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. | Bludigo Approved as Diagnostic Dye for Cystoscopic Assessment of Ureters |
Please login or register first to view this content.
